Saturday, October 17, 2026 · Edition updated 6:00 AM ETSAT, OCT 17 · 6 AM ET editionNext edition in Next --:--:--

Gene therapy with a virus carrier for ovary aging: a review of options

A summary of earlier studies · International journal of molecular sciences · Oct 16, 2026

What this means

This is a summary of ideas about using a harmless virus to deliver genes to the ovaries. It does not show the approach works in people.

Plain-English summary written by an AI model from the abstract. The original is below.

Tested inSummary of earlier studies
Who it was tested in
A review of earlier studies, no new testing reported
Kind of research
A summary of earlier studies

The science

Original title
AAV9 Gene Therapy for Ovarian Dysfunction and Reproductive Aging: Molecular Mechanisms, Therapeutic Targets, and Translational Perspectives.
Authors
Ullah S, Ullah I, Khalil BSF et al.
Journal
International journal of molecular sciences
Published
Oct 16, 2026
Study type
Review · in humans

Abstract

Female infertility is a growing concern in developed countries as delayed childbearing and ovarian dysfunction become more common. Ovarian decline is characterized by follicular depletion, granulosa cell dysfunction, aneuploidy, spindle assembly defects, mitochondrial damage, DNA damage, telomere shortening, stromal remodeling, and cellular senescence. Current approaches (hormonal therapy, assisted reproductive technologies, platelet-rich plasma, stem cells, extracellular vesicles, and mitochondrial-targeted treatments) offer partial benefit but do not directly correct the molecular drivers of ovarian dysfunction. Gene therapy via viral vectors offers a more direct strategy. Adeno-associated virus serotype 9 (AAV9) is attractive for its broad tropism, long-term transgene expression, favorable safety profile, and evidence of ovarian somatic cell transduction, particularly in granulosa and interstitial cells. It remains experimental, however, and requires rigorous evaluation of biodistribution, immune response, off-target effects, germline safety, embryo development, offspring health, and tumorigenic risk. This review summarizes the mechanisms of ovarian dysfunction, current therapeutic limitations, AAV9's advantages, delivery routes, candidate genes, and translational safety concerns.

Read it on PubMed ↗

Ullah S, Ullah I, Khalil BSF et al. AAV9 Gene Therapy for Ovarian Dysfunction and Reproductive Aging: Molecular Mechanisms, Therapeutic Targets, and Translational Perspectives. International journal of molecular sciences. 2026. doi:10.3390/ijms27198516. PMID: 42883763. https://pubmed.ncbi.nlm.nih.gov/42883763/

Report a problem